.svg){kind=small}
As clinical programmes progress, pharmacovigilance requirements become increasingly complex. Sponsors need access to specialist expertise, robust systems and regulatory oversight without necessarily building extensive internal infrastructure. Richmond provides flexible, inspection-ready pharmacovigilance support throughout clinical development, backed by more than two decades of practical clinical trial experience. Our services can be delivered as a standalone pharmacovigilance solution or integrated with Richmond's wider clinical development capabilities.
Speak to our Pharmacovigilance teamPharmacovigilance Services
Our pharmacovigilance services provide the expertise, systems and oversight required to manage safety throughout clinical development.
Study set-up and safety management.
Clinical trial case management, including SAE, SAR and SUSAR management.
Medical review and safety oversight.
Global expedited safety reporting.
Safety data reconciliation.
Pharmacovigilance oversight and governance.
DSUR authoring and global submissions.
Pharmacovigilance strategy and consultancy.
Quality oversight and compliance monitoring.
Our service is underpinned by a validated pharmacovigilance platform, robust SOPs and governance processes, supporting an inspection-ready operating environment.
Built Around Your Development Programme
Every development programme is different. Engage Richmond as your standalone pharmacovigilance provider or integrate the service with our wider capabilities across Clinical Operations, Medical, Regulatory and Data. Our focused operating model gives sponsors direct access to senior specialists throughout programme delivery, providing responsive support as requirements evolve.
Standalone Pharmacovigilance | Integrated Clinical Development
Why Richmond?
Practical clinical trial experience underpins our approach to pharmacovigilance. With more than 500 clinical studies completed across Phase I–III, Richmond understands how safety decisions interact with trial design, conduct, governance and participant management. Sponsors benefit from:
Senior expertise
Direct access to senior pharmacovigilance, medical, regulatory and clinical expertise.
Phase I–III experience
Experience across Phase I–III clinical development.
MHRA accredited
MHRA Phase I accreditation.
Complex & advanced studies
Experience supporting complex studies and advanced therapeutic modalities.
Scalable support
Flexible support that can scale alongside development programmes.
Validated & inspection-ready
Validated systems and inspection-ready quality processes.
Where services are integrated, our multidisciplinary teams work together to reduce handovers and support coordinated decision-making throughout study delivery.
Clinical Site Safety Management
Richmond also provides established safety management for clinical studies conducted at our research sites. Our site safety teams work closely with investigators and research physicians to support participant safety throughout study delivery. This includes: identification and documentation of adverse events; Serious Adverse Event (SAE) reporting; investigator assessment and medical oversight; safety information review and reconciliation; and communication with sponsors and relevant study teams. This established clinical safety experience provides an important foundation for Richmond's broader pharmacovigilance capabilities.
Built on Quality
Our approach is underpinned by validated systems, clear governance and experienced clinical and pharmacovigilance professionals. Quality, regulatory compliance and participant safety are embedded throughout our processes, giving sponsors confidence as their development programmes progress.
.avif)
Latest news
Richmond Pharmacology Appoints Adam Hurd as Operations Director
Upcoming Event
Women's Health Horizons 2026
